Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eravacycline - Tetraphase Pharmaceuticals

Drug Profile

Eravacycline - Tetraphase Pharmaceuticals

Alternative Names: TP-434; XERAVA

Latest Information Update: 18 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tetraphase Pharmaceuticals
  • Class Acetamides; Antibacterials; Pyrrolidines; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Intra-abdominal infections
  • Phase I Bacterial infections
  • No development reported Respiratory tract infections
  • Discontinued Urinary tract infections

Most Recent Events

  • 20 Dec 2018 Phase-I clinical trials in Bacterial infections (In adolescents, In children) in USA (IV) (NCT03696550)
  • 11 Oct 2018 Launched for Intra-abdominal infections in USA (IV) - First global launch
  • 04 Oct 2018 Tetraphase Pharmaceuticals plans a phase I trial for Bacterial infections (In children, In adolescents) in USA (IV) (NCT03696550)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top